Precision Psychiatry Market is projected to reach US$ 4.2 Bn by 2035, driven by rapid integration of AI and ML in psychiatric ...
As of Tuesday, December 23, Burning Rock Biotech Limited’s BNR share price has dipped by 9.53%, which has investors questioning if this is right time to buy.
TipRanks on MSN
Nutritional Growth Solutions director increases equity stake following shareholder approval
An announcement from Nutritional Growth Solutions Ltd. ( ($AU:NGS) ) is now available. Nutritional Growth Solutions Ltd has announced a change in ...
News-Medical.Net on MSN
Wasatch Biolabs announces co-marketing agreement with Agilent to advance native-read targeted sequencing
(WBL), a leader in native, long-read sequencing and epigenomic analysis, today announced a co-marketing agreement with Agilent Technologies to support the adoption of its Direct Targeted Methylation ...
Consumer Genetic Testing Market - Global Forecast 2025-2032" report has been added to ResearchAndMarkets.com's offering. The direct-to-consumer genetic testing market is undergoing rapid ...
MedPage Today on MSN
Overcoming CDK4/6 Inhibitor Resistance in HR-Positive/HER2-Negative Breast Cancer
In the CAPItello-291 trial of capivasertib plus fulvestrant, 73% of patients had already received a CDK4/6 inhibitor. As ...
Nutritional Growth Solutions Ltd. ( ($AU:NGS) ) has issued an announcement. Nutritional Growth Solutions has issued 12,965,673 fully paid ordinary ...
According to MarketsandMarkets™, The report Single-molecule Real-time (SMRT) Sequencing Market is projected to grow from USD ...
Consumer Genetic Testing Market - Global Forecast 2025-2032" report has been added to ResearchAndMarkets.com's offering. The ...
IntroductionThe global critical care diagnostics market is poised for steady expansion, projected to grow at a CAGR of around 6% over the next five years. This growth trajectory is supported by ...
The analysis reveals that genomics has seen explosive growth in clinical research over the past decade, with over 6,500 studies registered globally.
Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results